Savant Capital LLC Has $2.36 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Savant Capital LLC lifted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 1.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 70,831 shares of the biotechnology company’s stock after acquiring an additional 849 shares during the period. Savant Capital LLC’s holdings in Exelixis were worth $2,359,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in EXEL. Seizert Capital Partners LLC lifted its stake in Exelixis by 8.0% during the third quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock worth $12,195,000 after purchasing an additional 34,875 shares during the period. Los Angeles Capital Management LLC raised its holdings in shares of Exelixis by 124.0% in the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after buying an additional 991,494 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Exelixis by 60.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock worth $1,424,000 after buying an additional 20,641 shares during the period. Tri Ri Asset Management Corp acquired a new stake in Exelixis in the 3rd quarter valued at $4,396,000. Finally, CWA Asset Management Group LLC bought a new stake in Exelixis in the third quarter valued at $577,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on EXEL shares. StockNews.com downgraded shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Stifel Nicolaus boosted their price target on shares of Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Exelixis in a report on Monday, January 27th. JMP Securities reiterated a “market outperform” rating and issued a $41.00 target price on shares of Exelixis in a research note on Thursday, January 23rd. Finally, BMO Capital Markets lowered Exelixis from an “outperform” rating to a “market perform” rating and increased their price target for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.00.

Exelixis Stock Down 0.0 %

EXEL stock opened at $32.80 on Thursday. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $37.59. The business’s fifty day moving average is $34.24 and its 200-day moving average is $30.72. The company has a market cap of $9.37 billion, a P/E ratio of 21.03, a price-to-earnings-growth ratio of 0.63 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 22.43% and a return on equity of 20.99%. Research analysts anticipate that Exelixis, Inc. will post 1.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Exelixis news, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $35.27, for a total value of $352,700.00. Following the sale, the executive vice president now directly owns 278,665 shares in the company, valued at approximately $9,828,514.55. This trade represents a 3.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the completion of the transaction, the executive vice president now directly owns 486,059 shares of the company’s stock, valued at $17,823,783.53. This trade represents a 10.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 111,588 shares of company stock valued at $3,981,864 in the last 90 days. 2.85% of the stock is owned by insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.